GSK-649868
GSK-649868 is an experimental drug that was developed by GlaxoSmithKline for the treatment of insomnia. It acts as a selective antagonist for the orexin receptor, specifically the OX2 subtype, and has sedative effects.
Pharmacology[edit | edit source]
GSK-649868 is a selective antagonist for the orexin receptor, specifically the OX2 subtype. Orexin, also known as hypocretin, is a neuropeptide that regulates arousal, wakefulness, and appetite. By blocking the action of orexin, GSK-649868 promotes sleep.
Clinical trials[edit | edit source]
GSK-649868 has undergone Phase II clinical trials for the treatment of insomnia. However, as of 2021, it has not been approved for use by any regulatory authority.
See also[edit | edit source]
References[edit | edit source]
| GSK-649868 Resources | ||
|---|---|---|
|
| |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
